Profile
Full Name
Ultragenyx Pharmaceutical Inc.Ticker Symbol
RAREExchange
NASDAQSector
HealthcareIndustry
BiotechnologyCountry
United StatesIPO
January 31, 2014Indexes
Not includedWebsite
http://www.ultragenyx.comEmployees
1294Key Details
Price
$35.20
Market Cap
$3.26B(Mid cap)
Last Dividend
-
TTM Dividend Yield
-
Annual Revenue
$560.23M(+29.01% YoY)
Annual EPS
-$6.29(+23.76% YoY)
Next earnings date
May 2, 2025Next ex-dividend date
N/ANext split date
N/APrice
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Capitalization
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Market cap
Shares Outstanding
Technical Indicators
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Ultragenyx Pharmaceutical doesn't have historical dividend data
Income Statement
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Revenue
EPS
Profit
Expenses
EBIT & EBITDA
Balance Sheet
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Assets
Liabilities
Debt
Equity & Capital
Cash Flow Statement
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cashflow Activities
CAPEX
Free Cash Flow
Profitability Ratios
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Margins
ROA & ROE
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Leverage
Risk & Stability
Analyst ratings
Recent major analysts updates
Oct 22, 24 Cantor Fitzgerald
OverweightOct 21, 24 TD Cowen
BuyOct 1, 24 Cantor Fitzgerald
OverweightSep 26, 24 RBC Capital
OutperformSep 20, 24 Cantor Fitzgerald
OverweightSep 16, 24 Cantor Fitzgerald
OverweightAug 5, 24 Barclays
OverweightAug 2, 24 Wells Fargo
OverweightAug 2, 24 Wedbush
NeutralAug 2, 24 Goldman Sachs
BuyInstitutional Ownership
- What is the ticker symbol for Ultragenyx Pharmaceutical?
- Does Ultragenyx Pharmaceutical pay dividends?
- What sector is Ultragenyx Pharmaceutical in?
- What industry is Ultragenyx Pharmaceutical in?
- What country is Ultragenyx Pharmaceutical based in?
- When did Ultragenyx Pharmaceutical go public?
- Is Ultragenyx Pharmaceutical in the S&P 500?
- Is Ultragenyx Pharmaceutical in the NASDAQ 100?
- Is Ultragenyx Pharmaceutical in the Dow Jones?
- When was Ultragenyx Pharmaceutical's last earnings report?
- When does Ultragenyx Pharmaceutical report earnings?
- Should I buy Ultragenyx Pharmaceutical stock now?
What is the ticker symbol for Ultragenyx Pharmaceutical?
The ticker symbol for Ultragenyx Pharmaceutical is NASDAQ:RARE
Does Ultragenyx Pharmaceutical pay dividends?
No, Ultragenyx Pharmaceutical does not pay dividends
What sector is Ultragenyx Pharmaceutical in?
Ultragenyx Pharmaceutical is in the Healthcare sector
What industry is Ultragenyx Pharmaceutical in?
Ultragenyx Pharmaceutical is in the Biotechnology industry
What country is Ultragenyx Pharmaceutical based in?
Ultragenyx Pharmaceutical is headquartered in United States
When did Ultragenyx Pharmaceutical go public?
Ultragenyx Pharmaceutical's initial public offering (IPO) was on January 31, 2014
Is Ultragenyx Pharmaceutical in the S&P 500?
No, Ultragenyx Pharmaceutical is not included in the S&P 500 index
Is Ultragenyx Pharmaceutical in the NASDAQ 100?
No, Ultragenyx Pharmaceutical is not included in the NASDAQ 100 index
Is Ultragenyx Pharmaceutical in the Dow Jones?
No, Ultragenyx Pharmaceutical is not included in the Dow Jones index
When was Ultragenyx Pharmaceutical's last earnings report?
Ultragenyx Pharmaceutical's most recent earnings report was on Feb 13, 2025
When does Ultragenyx Pharmaceutical report earnings?
The next expected earnings date for Ultragenyx Pharmaceutical is May 2, 2025
Should I buy Ultragenyx Pharmaceutical stock now?
As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions